SCHEMBL2573704

SCHEMBL2573704

c1cc2ccc1CC1CCNCCCNCCCN1C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.39
HTR2B P41595 4/20 0.39
HTR2A P28223 1/20 0.36
L3MBTL3 Q96JM7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CXCR4 P61073 6/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
ADRA2C P18825 1/20 0.33
CCR2 P41597 1/20 0.33
CXCL12 P48061 1/20 0.33
BLM P54132 1/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxirane SCHEMBL608361 0.68 HTR6 (0.36) HTR2CHTR2BHTR2A
SCHEMBL8657726 0.67 L3MBTL3 (0.44) HTR2CHTR2BL3MBTL3L3MBTL1KMT2A
SCHEMBL12469538 0.67 HTR6 (0.54) HTR2CHTR2BHTR2AL3MBTL3L3MBTL1
SCHEMBL13836186 0.67
SCHEMBL28838207 0.67 L3MBTL3 (0.40) HTR2CHTR2BHTR2AL3MBTL3L3MBTL1
SCHEMBL11639039 0.66 HTR2C (0.58) HTR2CHTR2BHTR2AKMT2AHPGD
SCHEMBL51727 0.64 HTR6 (0.54) L3MBTL3L3MBTL1KMT2AHRH3HPGD
SCHEMBL993907 0.64 HTR6 (0.48) HTR2CHTR2BHTR2AL3MBTL3L3MBTL1
SCHEMBL6395460 0.64 HTR6 (0.54) L3MBTL3L3MBTL1KMT2AHRH3HPGD
SCHEMBL12730892 0.63 HTR6 (0.54) HTR2CHTR2BL3MBTL3L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391211-A1 METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER Genzyme Corporation (US) 2011-12-07 EP claimed
EP-2384115-A1 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES Genzyme Corporation (US) 2011-11-09 EP claimed
WO-2010088398-A1 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES GENZYME CORPORATION (US) 2010-08-05 WO claimed
WO-2010088401-A1 METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER GENZYME CORPORATION (US) 2010-08-05 WO claimed
EP-2384115-A1 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES Genzyme Corporation (US) 2011-11-09 EP disclosed
WO-2010088398-A1 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES GENZYME CORPORATION (US) 2010-08-05 WO disclosed
WO-2010025416-A1 CXCR4 ANTAGONISTS FOR KIDNEY INJURY GENZYME CORPORATION (US) 2010-03-04 WO disclosed
EP-2068868-A2 COMBINATION THERAPY Genzyme Corporation (US) 2009-06-17 EP disclosed
EP-2056853-A1 COMBINATION THERAPY Genzyme Corporation (US) 2009-05-13 EP disclosed
WO-2008019371-A1 COMBINATION THERAPY GENZYME CORPORATION (US) 2008-02-14 WO disclosed
WO-2008017025-A2 COMBINATION THERAPY GENZYME CORPORATION (US) 2008-02-07 WO disclosed
EP-1796716-A2 CHEMOKINE COMBINATIONS TO MOBILIZE PROGENITOR/STEM CELLS ANORMED INC. (CA) 2007-06-20 EP disclosed
WO-2006020891-A2 CHEMOKINE COMBINATIONS TO MOBILIZE PROGENITOR/STEM CELLS ANORMED INC. (CA) 2006-02-23 WO disclosed